Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.
Caribou Biosciences, Inc. (Nasdaq: CRBU) reported its first quarter 2024 financial results and pipeline progress, highlighting advancements in clinical-stage programs for hematologic malignancies and autoimmune diseases. With $345.9 million in cash, cash equivalents, and marketable securities, the company expects to fund operations into Q1 2026. Notable milestones include presenting clinical data at the 2024 ASCO Annual Meeting, initiating the GALLOP Phase 1 trial, and providing updates on ongoing trials. Despite a slight decrease in licensing and collaboration revenue, increased R&D and G&A expenses led to a net loss of $41.2 million for Q1 2024.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will participate in upcoming investor conferences, including the 2024 RBC Capital Markets Global Healthcare Conference and BofA Securities 2024 Health Care Conference. The company will present at these events, offering webcasts for more information.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.